A Basic Concept for PET-BNCT System
[10B]Boronophenylalanine (10B-BPA) has been used as a tumor selective boron carrier for boron neutron capture therapy (BNCT) in the treatment of malignant melanoma1. In the same way, it is thought to be a potential boron carrier for the treatment of malignant glioma2–4. Glioma infiltrates peripheral brain tissue and we always fall into the dilemma between resection and preservation of the infiltrated brain. Thus the treatment will be effective in these infiltrative tumors. In our studies of malignant glioma using positron emission tomography (PET), accumulation of 10B-BPA analog, [18F]fluoroboronophenylalanine (18F-10B-FBPA), in tumor lesion was dramatically revealed3. The metabolic analysis of this positron-emitting analog demonstrated that enhancement of the amino acid transport is a primary factor for the high accumulation3,5. [18F]Fluoroboronophenylalanine has been recognized as a compound that is incorporated into tumor cell selectively.
KeywordsPositron Emission Tomography Positron Emission Tomography Study Positron Emission Tomography Data Boron Neutron Capture Therapy Incorporation Rate
Unable to display preview. Download preview PDF.
- 2.J. A. Coderre, D.D.Joel, P.L. Micca, M.M. Nawrocky, D.N.Slatkin, Control ofintracerchra1 gliosarcomas in rats by boron neutron capture therapy with p-boronophenylalanine. Radiation Research 129: 290296, 1992.Google Scholar
- 3.S. Ueda, Y. Imahori, N. lbayashi, Y. Ohmori, K. Ono, T. Kobayashi, K. Akuta, The basic studies for boron neutron capture therapy (BNCT) of brain tumor using boronophenylalaninc. KURRI Prog. Rep. (Osaka): 304–305, 1992.Google Scholar
- 4.Y. Imahori, S. Ueda, N. lbayashi, Y. Ohmori, Metabolic evaluation of malignant brain tumor using ‘8F–10BPA by positron emission tomography to determine the feasibility of boron neutron therapy [abstract]. International Congress of Radiation Oncology: 285, 1993.Google Scholar
- 5.Y. Mishima, Y. Imahori, C. Honda, S. Ueda, T. Ido, In vivo diagnosis of human malignant melanoma using specific melanoma-seeking 18F-compound with positron emission tomography. Kyoto University Research Reactor Institute - Technical Report - (Osaka) 374,1–10, 1993.Google Scholar
- 6.Y. Mishima, Investigation for the extended application of melanoma boron neutron capture therapy. Kyoto University Research Reactor Institute–Technical Report- (Osaka) 356, 192–199, 1991.Google Scholar
- 7.S. Ueda, Y. Imahori, Y. Ohmori, E. Yoshino, K. Ono, T. Kobayashi, M. Takagaki, Y. Oda, T. Ido, Y. Mishima, Positron emission tomography and boron neutron capture therapy system to the patient with brain tumor -The first clinical trial using BPA-. In: Cancer Neutron Capture Therapy, Y. Mishima, ed., pp. 823–828 Plenum, New York, 1996.Google Scholar
- 9.K. Ishiwata, M. Shiono, K. Kubota, K. Yoshino, J. Hatazawa, T. Ido, C. Monda, M. Ichihashi and Y. Mishima, A unique in vivo assessment of 4-[’°B]borono-L-phenylalanine in tumor tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2[1sF]fluoro-L-phenylalaniIle. Melanoma Res. 2: 171–179, 1992.PubMedCrossRefGoogle Scholar